| Osprey Pharmaceuticals USA, together with its Montreal, Canada partner, Osprey Pharmaceuticals, Ltd., is developing a series of novel fusion protein therapeutics which selectively target and neutralize activated leukocytes that are implicated in a variety of inflammatory and immune disorders.
|
